Avendium
  • Home
  • Services
    • Quality Assurance
    • Audits
    • Regulatory Affairs
    • Commission, Qualification, and Validation
  • About
    • Overview
    • Mission
    • Team
    • Partners
    • Blog
  • Contact
Select Page

How to Integrate AI Into Quality and Regulatory Compliance

by tmourit | Jan 2, 2026 | Audits, Quality, Regulatory

Artificial intelligence is reshaping nearly every function in life sciences — from drug discovery to manufacturing optimization. Yet one of the most impactful, and often overlooked, applications of AI is in quality and regulatory compliance. For MedTech and life...

How do you prepare for an unannounced audit from a Notified Body or the FDA?

by tmourit | Dec 19, 2025 | Audits, Quality, Regulatory

Few phrases make quality teams more anxious than “unannounced audit.” Whether it’s a Notified Body conducting a surprise visit under the EU MDR/IVDR or an FDA investigator arriving unannounced for an inspection, these audits test your organization’s true level of...

What are the benefits of eQMS vs. paper-based systems for small manufacturers?

by tmourit | Dec 12, 2025 | Audits, Quality, Regulatory

For many small and growing life science manufacturers, managing quality can feel like a balancing act. On one hand, regulatory compliance is non-negotiable. On the other, budgets and staffing are often limited. Traditionally, companies have relied on paper-based...

How do you navigate regulatory submissions for ATMPs (gene and cell therapies)?

by tmourit | Dec 5, 2025 | Audits, Quality, Regulatory

Gene and cell therapies, collectively known as Advanced Therapy Medicinal Products (ATMPs), represent one of the most exciting and challenging frontiers in modern medicine. These therapies have the potential to treat, and even cure, diseases once considered...

What are the most common reasons regulatory submissions are delayed or rejected?

by tmourit | Nov 28, 2025 | Audits, Quality, Regulatory

Submitting a regulatory application, whether to the FDA, EMA, or another health authority, represents years of research, validation, and investment. Yet, even well-prepared companies experience delays, rejections, or major questions during the review process....

What Are the Differences Between FDA, EMA, and PMDA Approval Pathways?

by tmourit | Nov 21, 2025 | Audits, Quality, Regulatory

Bringing a new drug or biologic to market is a long and highly regulated process — and each major region has its own regulatory authority and approval pathway. In the United States, the FDA oversees product approval. In Europe, it’s the EMA, and in Japan, it’s the...
« Older Entries
Next Entries »
  • Facebook
Loading Comments...